SynAct Pharma AB
SYNACT SE0008241491
ICB 2010 : Health Care / Health CareAnnual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
227% | -43% | -90% | 0% | 28% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Jeppe Oevlesen CEO |
17.55 SEK |
2,757 Bought |
48,388 SEK |
25/06/2025 | 25/06/2025 |
Björn Westberg CFO |
17.52 SEK |
2,440 Bought |
42,749 SEK |
25/06/2025 | 25/06/2025 |
Thomas Jonassen EX OFF |
16.31 SEK |
18,800 Bought |
306,684 SEK |
25/06/2025 | 23/06/2025 |
Sten Sörensen DIR |
16.41 SEK |
3,048 Bought |
50,021 SEK |
25/06/2025 | 23/06/2025 |
Jeppe Oevlesen CEO |
16.04 SEK |
18,500 Bought |
296,819 SEK |
25/06/2025 | 19/06/2025 |
Thomas Boesen EX OFF |
16.22 SEK |
6,250 Bought |
101,380 SEK |
25/06/2025 | 19/06/2025 |
Anders Kronborg CB |
16.19 SEK |
6,150 Bought |
99,556 SEK |
25/06/2025 | 19/06/2025 |
Sten Sörensen DIR |
8.65 SEK |
5,780 Bought |
49,997 SEK |
03/01/2025 | 03/01/2025 |
Anders Kronborg CB |
8.65 SEK |
28,902 Bought |
250,002 SEK |
31/12/2024 | 30/12/2024 |
Björn Westberg CFO |
8.65 SEK |
11,560 Bought |
99,994 SEK |
03/01/2025 | 30/12/2024 |